

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A vaccine formulation comprising an immunogen, a preservative and suitable pharmaceutically acceptable excipients for vaccines ~~characterized in that~~ wherein the preservative ~~is~~ consisting essentially of a combination of at least two ~~paraben~~ esters of p-hydroxy benzoic acid selected from the group consisting of methyl, ethyl, propyl and butyl p-hydroxybenzoate and 2-phenoxyethanol.

Claim 2 (cancelled)

Claim 3 (previously presented)

A vaccine formulation according to claim 1, wherein the preservative is a combination of methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and 2-phenoxy ethanol.

Claim 4 (previously presented)

A vaccine formulation according to claim 1, wherein the excipients are selected from the group consisting of diluents, stabilizers, adjuvants, preservatives, buffers, surfactants, viscosity controlling agents and osmotic pressure controlling agents.

Claim 5 (previously presented)

A vaccine formulation according to claim 1, which further comprises aluminum hydroxide gel as an adjuvant.

Claim 6 (previously presented)

A vaccine formulation according to claim 1, which further comprises Quillaja saponin as an adjuvant.

Claim 7 (previously presented)

A vaccine formulation according to claim 1, wherein methyl p-hydroxybenzoate if present, is used in a concentration of 0.01 – 2.5 mg/ml, ethyl p-hydroxybenzoate if present, is used in a concentration of 0.01 – 0.7 mg/ml, propyl p-hydroxybenzoate if present, is used in a concentration of 0.01 – 0.5 mg/ml or butyl p-hydroxybenzoate if present, is used in a concentration of 0.01 – 0.16 mg/ml and 2-phenoxyethanol is used in a concentration of 0.4 – 26 mg/ml.

Claim 8 (previously presented)

A vaccine formulation according to claim 7, wherein methyl p-hydroxybenzoate is used in a concentration of about 1.3 mg/ml, propyl p-hydroxybenzoate is used in a concentration of about 0.2 mg/ml and 2-phenoxyethanol is used in a concentration of about 1.0 mg/ml.

Claim 9 (currently amended)

A base stock solution of excipients for the preparation of vaccines comprising an aluminum hydroxide gel and a combination of at least two ~~paraben~~ esters of p-hydroxybenzoic acid and 2-phenoxyethanol.

Claim 10 (currently amended)

A base stock solution of excipients for the preparation of vaccines comprising Quillaja saponin and a combination of at least two ~~paraben~~ esters of p-hydroxybenzoic acid and 2-phenoxyethanol.

Claim 11 (currently amended)

A ~~base~~ base stock solution of excipients for the preparation of vaccines comprising an aluminum hydroxide gel, Quillaja saponin and a combination of at least two ~~paraben~~ esters of p-hydroxybenzoic acid and 2-phenoxyethanol.

Claim 12 (new)

A vaccine formulation of claim 1 wherein the immunogen is inactivated porcine parvovirus.

Claim 13 (new)

A method of immunizing guinea pigs and pigs comprising administering to guinea pigs and pigs an immunizing amount of a vaccine formulation of claim 12.